+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Alpha-1 Antitrypsin Deficiency Pipeline Analysis and Outlook, 2019

  • ID: 4772479
  • Report
  • May 2019
  • Region: Global
  • 84 pages
  • VPA Research
1 of 3

FEATURED COMPANIES

  • Apic Bio Inc
  • Editas Medicine Inc
  • Grifols SA
  • Inhibrx LP
  • Intellia Therapeutics Inc
  • Kamada Ltd
  • MORE
Alpha-1 Antitrypsin Deficiency pipeline

Alpha-1 Antitrypsin Deficiency pipeline research report is a part of our 300+ Pharmaceutical and Healthcare disease pipeline report series. It provides detailed insights into Alpha-1 Antitrypsin Deficiency R and D activities including pipeline candidates, grants, developments, investments, technological advancements, and progress.

Extensive Coverage of Pipeline Candidates

The Alpha-1 Antitrypsin Deficiency report covers all the pre-clinical compounds and clinical compounds under evaluation for treatment of Alpha-1 Antitrypsin Deficiency as of 2019. All preclinical, research, discovery, pre registration, phase 1, phase 2, and phase 3 trials active are included in the study.

Over 10 descriptive details provided for each Pipeline Product

Complete analysis of therapeutics for treatment of Alpha-1 Antitrypsin Deficiency with details of current status of development, pipeline phase, drug target, mechanism of action (MoA), route of administration (RoA), participating companies, originator, collaborators and molecule type are included. The study also covers the historic developments, pharmacological action and recent developments associated with each drug.

Companies participating in Alpha-1 Antitrypsin Deficiency pipeline Profiled in detail

Key players actively participating in Alpha-1 Antitrypsin Deficiency pipeline are profiled along with their R&D progress in Alpha-1 Antitrypsin Deficiency treatment are provided. Companies /Universities /Institutes participating as originators, collaborators, licensors, investors, and marketing or developing companies are detailed in the report. Further, for all the developing companies, detailed profile is also provided.

Information Sourced from in-house Proprietary Databases

The report is developed using information from in-house database developed over years through daily updates from company reports, websites, events, conferences, news, announcements, clinical trial registries, regulatory authorities, universities and industry associations.

Report assists users in taking actionable steps

Alpha-1 Antitrypsin Deficiency pipeline report enables users to gain clear understanding into large and small companies participating in the pipeline and detailed insights into their product portfolio. The guide presents also available opportunities for new business in Alpha-1 Antitrypsin Deficiency treatment pipeline.

The report includes:
  • The research work provides comprehensive overview of Alpha-1 Antitrypsin Deficiency pipeline and treatment landscape
  • Complete list of drug candidates from discovery to pre-registration phases are analyzed
  • Companies and universities participating in the pipeline are analyzed in detail along with their drug development product portfolio
  • Detailed drug profiles of Alpha-1 Antitrypsin Deficiency pipeline compounds including status, phase, mechanism of action, route of administration, originators, licensing and collaborating companies, grants, technological advancements and investments are detailed
  • Research and Development progress and trial details, results wherever available, are also included in the Alpha-1 Antitrypsin Deficiency pipeline study
  • All recent news and developments related to Alpha-1 Antitrypsin Deficiency drugs are provided
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Apic Bio Inc
  • Editas Medicine Inc
  • Grifols SA
  • Inhibrx LP
  • Intellia Therapeutics Inc
  • Kamada Ltd
  • MORE
1. Introduction
1.1. Pipeline Snapshot, 2019
1.2. Overview Pipeline Activities in 2019

2. Alpha-1 Antitrypsin Deficiency Disease Overview

3. Alpha-1 Antitrypsin Deficiency Research and Development Pipeline Trends
3.1. Pipeline Drugs under development by phase, 2019
3.2. Pipeline Drugs by Mechanism of Action, 2019
3.3. Pipeline Drugs by Route of Administration, 2019
3.4. Pipeline Drugs by Company, 2019
3.5. Pipeline Drugs by Molecule Type, 2019

4. Alpha-1 Antitrypsin Deficiency Pre-clinical and Discovery Phase Drug Profiles
4.1. Drug Name/Alternative Names
4.2. Originator
4.3. Licensor/Developer/Collaborators
4.4. Class
4.5. Mechanism of Action
4.6. Route of Administration
4.7. Orphan Drug Status
4.8. New Molecular Entity
4.9. Current Status
4.10. Trial Landscape
4.11. Development History

5. Alpha-1 Antitrypsin Deficiency Clinical Phase Drug Profiles
5.1. Drug Name/Alternative Names
5.2. Originator
5.3. Licensor/Developer/Collaborators
5.4. Class
5.5. Mechanism of Action
5.6. Route of Administration
5.7. Orphan Drug Status
5.8. New Molecular Entity
5.9. Current Status
5.10. Trial Landscape
5.11. Development History

6. Company Profiles
6.1. Alpha-1 Antitrypsin Deficiency companies
6.1.1 Business Profile
6.1.2. Pipeline Products
6.1.3. Alpha-1 Antitrypsin Deficiency Activities

7. Recent News Landscape

8. Appendix
8.1. Sources and Research Methodology
8.2. Publisher Expertise
8.3. Database and Custom Services
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Adverum Biotechnologies Inc
  • Alnylam Pharmaceuticals Inc
  • Apic Bio Inc
  • Applied Genetic Technologies Corporation
  • Arrowhead Pharmaceuticals Inc
  • Editas Medicine Inc
  • Grifols SA
  • Inhibrx LP
  • Intellia Therapeutics Inc
  • International Stem Cell Corp
  • Kamada Ltd
  • Logicbio Therapeutics Inc
  • Mereo BioPharma Group plc
  • OncBioMune Pharmaceuticals Inc
  • Promethera Biosciences SA
  • Santhera Pharmaceuticals
  • Vertex Pharmaceuticals Inc
  • Z Factor Ltd
Note: Product cover images may vary from those shown
Adroll
adroll